Defining Progression in Metastatic Kidney Cancer
3 Bekeken
• 06/26/23
0
0
insluiten
administrator
abonnees
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
Laat meer zien
Facebook Reacties
SORT BY-
Top Reacties
-
Laatste Reacties